Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 4,800 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Not applicable Interventional

Study Comparing At-Home Mobile Spirometry to In-Clinic in Moderate Asthma Participants Taking Long-Acting Beta Agonist

NCT05757908
View directory record Official record
Conditions
Moderate Asthma
Interventions
Long-Acting Beta Agonist
Drug
Lead sponsor
Koneksa Health
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
9
States / cities
Birmingham, Alabama • Columbus, Georgia • North Dartmouth, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Detection of Bovine and Soy Proteins in Human Milk

NCT04851340
View directory record Official record
Conditions
Microbiome, Stress, Food Allergy in Infants
Interventions
Cow's Milk, Soy Milk
Other
Lead sponsor
University of Idaho
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Moscow, Idaho
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 3 Interventional

A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults

NCT00116818
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X aqueous nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 21, 2026, 4:26 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Molecular Basis of Food Allergy

NCT01832324
View directory record Official record
Conditions
Food Allergy, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 65 Years
Enrollment
5,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

Olopatadine Eye Drops and Allergy Skin Testing

NCT00775658
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis
Interventions
olopatadine, placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354

NCT00638989
View directory record Official record
Conditions
Asthma, Healthy
Interventions
CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), CAT-354 300 mg (subcutaneous)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

NCT00659750
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Encinitas, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

NCT01809691
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700, Bicalutamide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
560
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 374 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Free Fatty Acids: Threshold Repeatability Study

NCT01550120
View directory record Official record
Conditions
Taste, Non-esterified Fatty Acids
Interventions
Not listed
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthful Seafood Consumption for Sensitive Populations

NCT01123759
View directory record Official record
Conditions
Infant Brain Health
Interventions
Feeding low mercury fish
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Tallahassee, Florida • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 21, 2026, 4:26 AM EDT
Active, not recruiting No phase listed Observational

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

NCT02848560
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1 Interventional

Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction

NCT02266355
View directory record Official record
Conditions
Colon Cancer
Interventions
Omalizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Phase II HDM-SPIRE Safety and Efficacy Study

NCT02150343
View directory record Official record
Conditions
Rhinoconjunctivitis
Interventions
HDM-SPIRE, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
56
States / cities
Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

NCT02495168
View directory record Official record
Conditions
Asthma
Interventions
Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate), Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Surprise, Arizona • Huntington Beach, California • San Jose, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

NCT06059690
View directory record Official record
Conditions
Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
Interventions
pH Measurement of in vivo tissue
Diagnostic Test
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

NCT01033123
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BSI-201
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

NCT06362759
View directory record Official record
Conditions
Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, C-Reactive Protein, High Sensitivity C-Reactive Protein, Hs-CRP, hsCRP
Interventions
TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG, Placebo
Drug · Other
Lead sponsor
Tourmaline Bio, Inc., a Novartis Company
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 21, 2026, 4:26 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)

NCT07780643
View directory record Official record
Conditions
Asthma
Interventions
GSK5784283, Placebo, Standard of care
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

NCT00061308
View directory record Official record
Conditions
Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
Interventions
Topotecan, Gemcitabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
15
States / cities
Los Gatos, California • Santa Rosa, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 21, 2026, 4:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 21, 2026, 4:26 AM EDT
Completed No phase listed Observational

Examining the Link Between Depression and Seasonal Allergies

NCT00770068
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT04250350
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

NCT05142774
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
102
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 21, 2026, 4:26 AM EDT